Tenax Therapeutics (TENX) Receivables - Other (2012 - 2013)
Tenax Therapeutics (TENX) reported Receivables - Other of $500000.0 for Q2 2013, up 3244.48% on a YoY basis from $14950.0 in Q2 2012, and up 1615.62% sequentially from $29144.0 in Q1 2013.
Tenax Therapeutics (TENX) Receivables - Other (2012 - 2013) Analysis & Trends
Tenax Therapeutics (TENX) has 2 years of Receivables - Other data on file, last reported at $500000.0 in Q2 2013.
- For the quarter ending Q2 2013, Receivables - Other rose 3244.48% year-over-year to $500000.0; the trailing twelve-month figure through Apr 2013 stood at $500000.0 (up 3244.48% YoY), and the FY2013 full-year result was $500000.0, up 3244.48% from the prior year.
- Receivables - Other climbed to $500000.0 in Q2 2013, from $29144.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $500000.0 in Q2 2013 to a low of $14950.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Tenax Therapeutics | 67,856.40 | 67,856.40 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2013 | 500,000.00 |
| Apr 30, 2013 | 500,000.00 |
| Jan 31, 2013 | 29,144.00 |
| Jan 31, 2013 | 29,144.00 |
| Jul 31, 2012 | 50,701.00 |
| Jul 31, 2012 | 50,701.00 |
| Apr 30, 2012 | 14,950.00 |
| Apr 30, 2012 | 14,950.00 |